DAFNA Capital Management »

Seaport Therapeutics shares owned by DAFNA Capital Management

Quarter-by-quarter ownership of Seaport Therapeutics shares owned by DAFNA Capital Management from 13F filings

Historical chart of DAFNA Capital Management investment in Seaport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Seaport Therapeutics held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Seaport Therapeutics by DAFNA Capital Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $704k 32k 21.72

More positions owned by DAFNA Capital Management

Revolution Medicines (RVMD)
Spdr S&p Biotech Etf Etf (XBI)
Compass Pathways Sponsored Ads (CMPS)
Stereotaxis Com New (STXS)
Nektar Therapeutics Com New (NKTR)
Denali Therapeutics (DNLI)
Ideaya Biosciences (IDYA)
AtriCure (ATRC)
Xenon Pharmaceuticals (XENE)
Cytokinetics Com New (CYTK)
Arcus Biosciences Incorporated (RCUS)
Ascendis Pharma A/s Ord Shs (ASND)
Neurocrine Biosciences (NBIX)
Axogen (AXGN)
Insulet Corporation (PODD)

View all positions for DAFNA Capital Management

Top funds holding Seaport Therapeutics

Arch Venture Corp
General Atlantic
Sofinnova Ventures
Goldman Sachs Group
Trv Gp Vi
Canada Pension Plan Investment Board
Jpmorgan Chase & Co
Foresite Capital Management VI
FMR
Bellevue Group
Siren
Jennison Associates
RA Capital Management
Vanguard Capital Management
Woodline Partners

View all funds holding Seaport Therapeutics